跳转至内容
Merck
CN

EHU080901

MISSION® esiRNA

targeting human DLX4

登录 查看组织和合同定价。

选择尺寸

关于此项目

NACRES:
NA.51
UNSPSC Code:
41105324

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

MISSION® esiRNA, targeting human DLX4

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

GGAGAAAAAGGAATGGAGCAGAGCCTGTACCCCTAACCCTAACAGCTAAATCAAGGACCTCAGCCTTATATAATCATTGTCCCCACCACTACCATGGACTGGACACCTTCACTCCAGCTGGACAAAGACTCTGGAGAGAGAGCCATTGGCTGGAGTTGAGACTGTCCCCAGAACCCTTGGTCTTGCCACTCCCCCACTCCTTCTTCCCTCTCTCCCTTTCTCCTCTCCCTGCTTTCTTGAAAAGGACTGAATCGCCACTACAGCCTGGGTGCAAAATCAGCAAGAAACATTGAGTATTTTTTTTTCTTTGTATGCCTTTGGCCTTGCACAACCCATTTGTGAGCAAAAGCAGAAGTGGACCACCATCAGCTCCCACCCACCCAGCGATTTTTCCTTGGAGGTCA

Ensembl | human accession no.

ENSG00000108813

NCBI accession no.

NM_138281

shipped in

ambient

storage temp.

−20°C

Quality Level

100

Gene Information

human ... DLX4(1748), DLX4(1748)

相关类别

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Yinxiang Lv et al.
Drug design, development and therapy, 10, 3053-3064 (2016-10-13)
Resistance to chemotherapeutic drugs is a major obstacle in non-small cell lung cancer (NSCLC) therapy. The molecular determinants of NSCLC resistance to doxorubicin are unknown. In the present study, we investigated whether topoisomerase IIβ binding protein 1 (TopBP1) was involved
Yinxiang Lv et al.
Anti-cancer drugs, 28(8), 861-868 (2017-06-20)
Calcein acetoxymethyl ester (calcein-AM) treatment has been reported to exert antitumor effects in certain cancer cells; however, the detailed mechanism of action of calcein-AM in cancers remains unclear, especially in nonsmall cell lung cancer (NSCLC). This study focused on the
Balabhadrapatruni V S K Chakravarthi et al.
Molecular cancer research : MCR, 16(7), 1125-1137 (2017-10-14)
In aggressive prostate cancers, the oncoprotein STMN1 (also known as stathmin 1 and oncoprotein 18) is often overexpressed. STMN1 is involved in various cellular processes, including cell proliferation, motility, and tumor metastasis. Here, it was found that the expression of
Shiyuan Hong et al.
Oncogene, 38(17), 3274-3287 (2019-01-12)
High-risk human papillomaviruses (HPVs) constitutively activate ataxia telangiectasia mutated (ATM) and ataxia telangiectasia- and Rad3-related (ATR) DNA damage repair pathways for viral genome amplification. HPVs activate these pathways through the immune regulator STAT-5. For the ATR pathway, STAT-5 increases expression
Rune Troelsgaard Pedersen et al.
The Journal of cell biology, 210(4), 565-582 (2015-08-19)
Genome integrity is critically dependent on timely DNA replication and accurate chromosome segregation. Replication stress delays replication into G2/M, which in turn impairs proper chromosome segregation and inflicts DNA damage on the daughter cells. Here we show that TopBP1 forms

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持